Can the revised IPSS predict response to erythropoietic-stimulating agents in patients with classical IPSS low or intermediate-1 MDS?

To the editor: The “classical” International Prognostic Scoring System (IPSS), based on cytogenetics, marrow blast percentage, and number of cytopenias, has played a major role in prognosis assessment in myelodysplastic syndromes (MDS).[1][1] The recently published revised IPSS (IPSS-R), using

[1]  B. Biggs,et al.  Control of iron deficiency anemia in low- and middle-income countries. , 2013, Blood.

[2]  A. Stamatoullas,et al.  Long-term outcome of anemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agents , 2013, Leukemia.

[3]  Luca Malcovati,et al.  Revised international prognostic scoring system for myelodysplastic syndromes. , 2012, Blood.

[4]  C. Steidl,et al.  New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Diego Moretti,et al.  Iron Fortification Reduces Blood Lead Levels in Children in Bangalore, India , 2006, Pediatrics.

[6]  S. K. Kim,et al.  Association between blood lead concentrations and body iron status in children , 2003, Archives of disease in childhood.

[7]  I. Dybedal,et al.  A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony‐stimulating factor: significant effects on quality of life , 2003, British journal of haematology.

[8]  T Hamblin,et al.  International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.

[9]  R. Seeler,et al.  Interaction of iron deficiency and lead and the hematologic findings in children with severe lead poisoning. , 1988, Pediatrics.